A Phase 1 study of TVB-2640 in Patients with Solid Tumours
Research type
Research Study
Full title
A phase 1, first-in-human study of escalating doses of oral TVB-2640 in patients with solid tumours
IRAS ID
158417
Contact name
Hendrik-Tobias Arkenau
Contact email
Sponsor organisation
3V Biosciences
Eudract number
2014-002051-26
Research summary
TVB-2640 is a drug designed to inhibit the enzyme fatty acid synthase (FASN). FASN is found in many cancer types (breast, ovarian, prostate, colon, pancreatic cancers and non-Hodgkins Lymphoma)and has been associated with increased patient death.
The study will be carried out in phase 1 research centres.
Patients can have as many cycles of 3 weeks as they can tolerate. The study is expected to last 2 years.
Phase 1 of the study will be carried out in the US and UK and will recruit 131 pts over approx. 10 sites.
The study is expected to last 2 years in the UK.REC name
London - Surrey Borders Research Ethics Committee
REC reference
14/LO/1358
Date of REC Opinion
28 Aug 2014
REC opinion
Unfavourable Opinion